Back

FDA Grants Nelkarmi Accelerated Approval for Lung Cancer

The U.S. Food and Drug Administration approved Nelkarmi, the brand name for neladalkib, through its accelerated pathway on November 17, 2026, according to the agency’s notice. The indication covers adults whose ALK-positive non-small cell lung cancer is locally advanced or metastatic, subject to requirements for previous treatment.

According to the FDA, patients must previously have received treatment for unresectable locally advanced or metastatic disease. Eligibility requires either alectinib as the patient’s sole previous ALK tyrosine kinase inhibitor, or platinum-based chemotherapy together with at least two previous ALK inhibitors.

GSK’s November 17 announcement states that the accelerated approval rests on the proportion of patients with tumor responses and the duration of those responses. The announcement also states that continued approval may depend on a confirmatory trial establishing and characterizing clinical benefit.

The FDA’s evaluation used ALKOVE-1, an open-label study conducted at multiple centers with several cohorts and a single treatment arm. An independent panel, blinded to treatment information, assessed confirmed tumor responses and their duration using RECIST version 1.1, the study’s principal efficacy measures.

For the 67 participants who had received no ALK inhibitor other than alectinib, the FDA documented a confirmed response rate of 49%, with a 95% confidence interval of 37%–62%. Within the responding group, responses persisted for six months or longer in 76% and for 12 months or longer in 52%.

A separate cohort comprised 155 patients previously given platinum-based chemotherapy and two or more ALK inhibitors. The agency recorded confirmed responses in 32%, with a 95% confidence interval of 24%–40%. Among those who responded, 69% maintained their response for at least six months; the corresponding proportion at 12 months was 51%.

For dosing, the FDA recommends a 150 mg oral dose each day, taken at a consistent time. Food is optional, and the recommended treatment period continues until disease progression or toxicity becomes unacceptable.

Safety warnings in the agency’s notice cover toxicity affecting the liver, kidneys and eyes, along with elevated creatine phosphokinase and embryo-fetal toxicity. The notice identifies adverse reactions affecting at least 20% of patients: fatigue, edema, peripheral neuropathy, dysgeusia, constipation, musculoskeletal pain and hepatotoxicity.

GSK stated in its November 17 announcement that Nelkarmi belongs to the portfolio obtained through its recent Nuvalent acquisition. The FDA’s approval notice lists Nuvalent, Inc., and identifies neladalkib as the drug sold under the Nelkarmi name.

* This article is based on publicly available information at the time of writing.